Guidance for the prevention and management of adverse events in patients receiving dinutuximab beta therapy
The guidelines for the prevention and management of adverse events in patients receiving dinutuximab beta therapy provide recommendations for assessing the risk of development, prevention and management of adverse events.
Authors
- А. M. Suleymanova (ORCID: https://orcid.org/0000-0002-5489-1879)
- G. B. Sagoyan (ORCID: https://orcid.org/0000-0002-7846-3473)
- С. Р. Варфоломеева (ORCID: https://orcid.org/0000-0001-6131-1783)
- Ruzanna Papyan (ORCID: https://orcid.org/0000-0003-1949-6280)
- Т. С. Белышева (ORCID: https://orcid.org/0000-0001-5911-553X)
- S. A. Kulyova (ORCID: https://orcid.org/0000-0003-0390-8498)
- N. V. Matinyan
- К. И. Киргизов (ORCID: https://orcid.org/0000-0002-2945-284X)
- M. V. Rubanskaya (ORCID: https://orcid.org/0000-0002-1016-539X)
- Alena Galanskova
- D. D. Sidorova
- D. А. Terekhina
Institutions
- Pirogov Russian National Research Medical University (RU)
- Ministry of Health of the Russian Federation (RU)
- Yerevan State Medical University (AM)
Publication Details
- Journal
- Russian Journal of Pediatric Hematology and Oncology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.21682/2311-1267-2025-12-1-77-88
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00